| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.9 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.0043 | 0.9 |